Logo

Quidel Reports Preliminary Q4, FY2014 Revenues

Jan 12, 2015 | staff reporter

NEW YORK (GenomeWeb) – Quidel said today that it expects revenues in the range of $63 million to $64 million for the fourth quarter and $182 million to $183 million for full-year 2014.

The preliminary results are based on management's initial analysis of operations for the quarter ended Dec. 31, Quidel said in a filing with the US Securities and Exchange Commission.

The Q4 revenue projection would represent a 26 percent to 28 percent increase year over year. On average, analysts were estimating $57.3 million in revenues for the company in Q4.

Filed under

Business News
Quidel
financial estimates
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.